Evidence method
Level · gp.fundamentals.capex_revenue_ratio
3.40% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Dec 31, 2023
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-24-000008General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
5.70% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
76.23% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
4.88% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
85.33% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-15.43% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
54.94% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
12.12% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 2.28%
- Current
- 3.40%
- Delta
- 1.13%
- Previous
- 47.89%
- Current
- 5.70%
- Delta
- -42.19%
- Previous
- 183.96%
- Current
- 76.23%
- Delta
- -107.73%
- Previous
- 12.76%
- Current
- 4.88%
- Delta
- -7.88%
- Previous
- 89.41%
- Current
- 85.33%
- Delta
- -4.08%
- Previous
- 28.50%
- Current
- -15.43%
- Delta
- -43.93%
- Previous
- 33.73%
- Current
- 54.94%
- Delta
- 21.20%
- Previous
- 8.52%
- Current
- 12.12%
- Delta
- 3.61%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Analogous To · ALNY state analogue 3 →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_INCREASED →Transitioned To · ALNY CASH_GENERATION_DECREASED →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_DECREASED →Transitioned To · ALNY MARGIN_DECREASED →Transitioned To · ALNY PROFITABILITY_DECREASED →Transitioned To · ALNY R_AND_D_INTENSITY_INCREASED →Transitioned To · ALNY SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.